LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced the publication of...
Pinteon Therapeutics today announced the launch of a Phase 1 trial of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease. Pinteon is funded by a $17 million Series A from Morningside Ventures and led by an...
Coalition for Epidemic Preparedness Innovations (CEPI) partnership will support Themis’ development and manufacturing of vaccine candidate VIENNA, Austria & OSLO, Norway–(BUSINESS WIRE)– Themis Bioscience and CEPI – the Coalition for Epidemic...
– Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston – STRO-002 was well tolerated in patients with advanced relapsed and refractory ovarian cancer and demonstrated preliminary...
Pivotal results expected in March/April 2020 Details of the program to be reviewed at company’s Investor Day today in NY REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company,...
Email
Text